A single platform for managing regulatory & clinical trial documents
The documentation burden is only growing for clinical research sites. Why waste valuable time and resources manually printing, scanning, and routing documents and correspondence?
Discover the top 5 requirements when evaluating an effective eReg/eISF clinical trial solution
You want the advantages of an e-Regulatory / eISF clinical trial solution: better oversight, greater efficiency, and hassle-free audit readiness. But how do you know you’re choosing the right solution?
Consider these five critical areas when evaluating systems to drive efficiencies and time savings throughout your entire clinical research ecosystem.
Complion offers a sponsor-approved, purpose-built solution for collecting and managing all of your clinical trial documentation during the COVID-19 pandemic and beyond. Learn about how your site can benefit from leveraging our eReg solution.
Access documents from any device
Leverage your current workflows to create your patient binder, central binder, and regulatory binders without the hassle. Everything is easily accessible from any device in our cloud-based solution.
21 CFR Part 11 Compliant
Our platform is 100% Part 11 compliant and meets ICH GCP. Unlike a shared drive, CTMS or sponsor portal, it allows you to control and maintain your documentation entirely electronically.
Save money
Not only will our solution save you time, but it can help reduce, if not eliminate, costs associated with materials and archiving. Additionally, it is monitor-accepted and reimbursable.
Committed to your success
Not only is our software user-friendly, but our experienced team of eRegulatory professionals can get you up and running quickly. You'll enjoy access to the combined knowledge shared in our customer community.
“What you do really, really well is service and support. You are more than willing to help and provide guidance whenever we need it. Complion is the only vendor we work with that is truly site focused and site driven. We always feel like a priority.”Dustin Caldwell, Director of Operations, OptiMed Research